MTOR and glioblastoma: They found that PRMT5 activity was stimulated by mTOR inhibitors, which could explain resistance to mTOR inhibition, and that the concurrent inhibition of PRMT5 and mTOR pathways led to synergistic anti-proliferative effects both in GBM cell lines and in a xenograft model (Holmes et al. 2019).